FAS and cancer: The ether phospholipid edelfosine (1-O-octadecyl-2-O-methoxy-rac-glycero-3-phosphocholine), considered as the APL prototype, is a rather selective antitumor drug [25-27] that preferentially accumulates in tumor cells [25, 26, 28, 29], and promotes apoptosis in a wide number of both hematological and solid tumor-derived cancer cells through lipid raft reorganization, leading to the activation of the death receptor Fas/CD95 independently of its natural ligand FasL/CD95L [26-28, 30-34], or by eliciting an endoplasmic reticulum (ER) stress response [34-36].